The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | ALPHA3 study: first-line consolidation with cema-cel in MRD-positive LBCL after standard therapy
Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ongoing Phase II ALPHA3 study (NCT06500273) evaluating first-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) who achieve PET-negative remission but remain circulating tumor DNA (ctDNA)-positive. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
At the ASH 2025 meeting, we’re excited to have an update on the ongoing ALPHA3 study. This is a study that is the first of its kind evaluating patients who have first-line large B-cell lymphoma treatment. At the end of treatment, they have a PET-CT scan showing a complete response, but they have a blood test, an ultra-sensitive blood test looking at ctDNA that shows they have residual disease...
At the ASH 2025 meeting, we’re excited to have an update on the ongoing ALPHA3 study. This is a study that is the first of its kind evaluating patients who have first-line large B-cell lymphoma treatment. At the end of treatment, they have a PET-CT scan showing a complete response, but they have a blood test, an ultra-sensitive blood test looking at ctDNA that shows they have residual disease. They’re then eligible for the ALPHA3 trial where they’re randomized to either have observation or to receive an allogeneic CD19 CAR-T cell called cema-cel. On this clinical trial, patients are being randomized for what could be a new strategy of treating patients with a minimal amount of disease as opposed to waiting for a full relapse. This study is up and running and rapidly enrolling and we’re eagerly anticipating the results.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
